TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02987751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine + Glulisine
Description: Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed analogue insulin (70/30)
Description: Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
Study: NCT03617952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3 Bio Intervention
Description: Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3 Bio Intervention
Description: Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
Study: NCT04343872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Receive lifestyle modification alone
Description: Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive lifestyle modification alone
Description: Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
Study: NCT03011281

Intervention type: DRUG
Intervention: Tofacitinib
Study: NCT03490825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Description: Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Description: Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal timing
Description: Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal timing
Description: Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Meal timing
Description: Subjects are instructed to maintain their habitual meal timing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Meal timing
Description: Subjects are instructed to maintain their habitual meal timing.
Study: NCT00992758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 Anti-B1 Antibody
Description: Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached.
Study: NCT04019353

Intervention type: GENETIC
Intervention: cf-DNA Collection
Description: For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations.
Study: NCT05757648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-buffered Anesthetic
Description: non-buffered LA, 2% lidocaine with epinephrine 1:100,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Anesthetic
Description: A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onset
Description: The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge.
Study: NCT03987477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation bias modification program
Description: Brief online program aimed at the modification of negative interpretation biases.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Description: Waiting list procedure for the control group.
Study: NCT02163824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25%
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1.0%
Description: KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 0.25%
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 1.0%
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study: NCT02249936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study: NCT03915171

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next generation sequencing
Description: NGS can provide genetic and MSI test for patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next generation sequencing
Description: NGS can provide genetic and MSI test for patients
Study: NCT02581306

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
Study: NCT02982902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV specific adoptive t-cells
Description: It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
Study: NCT00619515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implanted fiducial-based imaging
Description: Undergo fiducial placement imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
Study: NCT04343872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Description: The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
Study: NCT01850446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficacy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Safety and Efficacy
Study: NCT02295553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT03820674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Conservation plus Problem Solving Therapy
Description: EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
Study: NCT03725085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex™ extended-release (SE)
Description: 2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
Study: NCT01934257

Intervention type: OTHER
Group type: OTHER
Intervention: Marketed milk-based lactose-containing infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Marketed milk-based lactose-free infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Marketed soy-based lactose-free infant formula
Study: NCT00327106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (Exacyl)
Description: 15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
Study: NCT00724178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol plus calcium carbonate
Description: oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol plus calcium carbonate
Description: oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
Study: NCT02408133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
Study: NCT04092153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasy
Description: Surgical implantation of prosthetic knee using robotic-arm assist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasy
Description: Surgical implantation of prosthetic knee using robotic-arm assist
Study: NCT00925262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nonspecific counseling
Description: nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
Study: NCT02102789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI
Description: Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Study: NCT01485094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6010
Description: Oral solution given once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily.
Study: NCT00836589

Intervention type: DEVICE
Intervention: ICD Therapy - ICD Lead Registry
Description: Collecting long-term safety and efficacy data on a family of market-released ICD leads.
Study: NCT02997943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment: APP
Description: Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment: APP + Coaching
Description: Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Strategy: Modest Step-up
Description: In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
Study: NCT02506712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartDrive assisting device
Description: oxygen consumption
Study: NCT02997943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Strategy: Vigorous Step-up
Description: In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
Study: NCT02506712

Intervention type: DEVICE
Group type: OTHER
Intervention: SmartDrive assisting device
Description: oxygen consumption

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard manuel wheelchair
Description: oxygen consumption

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard manuel wheelchair
Description: oxygen consumption
Study: NCT01733875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.03 mg
Description: A single dose of CC-220 0.03 mg will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.1 mg
Description: A single dose of CC-220 0.1 mg will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.3 mg
Description: A single dose of CC-220 0.3 mg will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 1 mg
Description: A single dose of CC-220 1 mg will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 2 mg
Description: A single dose of CC-220 2 mg will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of placebo will be administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 4 mg will be administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 6 mg will be administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
Study: NCT01263964

Intervention type: PROCEDURE
Intervention: coronary angiogram
Description: coronary angiogram

Intervention type: PROCEDURE
Intervention: coronary angiogram
Description: coronary angiogram
Study: NCT03378817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOPE
Description: HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage
Description: No intervention
Study: NCT01784731

Intervention type: BEHAVIORAL
Intervention: Willingness to pay
Study: NCT02736058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans- abdominal sonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-vaginal sonography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-operative pathological specimen examination
Study: NCT01332123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alignment perturbations
Description: Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)